Finland· FI-REL-REL45316
Dutrebis
A lamivudin und raltegravir product containing lamivudine + raltegravir potassium, registered in Finland by Merck Sharp & Dohme Limited. The same ATC class is registered in 2 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Lamivudin und raltegravir is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AR16 (lamivudin und raltegravir), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 2 of them publish a price we can compare per daily dose
Lamivudin und raltegravir · ATC J05AR16
2 / 19 countries
- Belgiumprice
- Finlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Lamivudine + Raltegravir potassium
- Manufacturer
- Merck Sharp & Dohme Limited
- Country
- Finland (FI)
- ATC code
- J05AR16
- ATC class
- Lamivudin und Raltegravir
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J05AR16
Lamivudin und raltegravir, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6253ada-36b9-42ce-8c0a-8013399b9315 GET /v1/drugs/b6253ada-36b9-42ce-8c0a-8013399b9315?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "tabletti, kalvopäällysteinen",
"route": null,
"ddd_unit": null,
"strength": "150 mg / 300 mg",
"atc_label": "lamivudiini ja raltegraviiri",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/15/995/001",
"fimea_rel_id": "REL45316",
"authorised_at": "2015-03-26"
}See everything about lamivudin und raltegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.